Biotech Veteran Lou Reese Joins MAHA Action Board to Challenge Chronic Disease Status Quo
Event summary
- Lou Reese, biotech pioneer with 20+ years of experience, joins MAHA Action's Board of Directors on April 21, 2026.
- Reese has led companies developing peptide-based medicines targeting chronic diseases at a fraction of conventional treatment costs.
- His immunotherapy platform has seen billions of veterinary doses deployed and thousands of human clinical trial participants.
- Reese advocates for regenerative agriculture practices aligning with MAHA Action's agenda.
The big picture
Lou Reese's appointment brings strategic expertise in biotechnology and regenerative agriculture to MAHA Action, aligning with the organization's mission to challenge the status quo in healthcare. His work on affordable chronic disease treatments and sustainable farming models positions MAHA Action at the forefront of a movement seeking systemic change in America's public health policy.
What we're watching
- Disruptive Innovation
- How Reese's peptide-based medicines will challenge the $100,000+ per year monoclonal antibody treatments.
- Regulatory Capture
- Whether MAHA Action can effectively combat corporate and regulatory capture in public health policy.
- Movement Momentum
- The pace at which MAHA Action can build political and cultural infrastructure to reverse chronic disease epidemic.
Related topics